Showing 2531-2540 of 3315 results for "".
- Melt Pharmaceuticals Doses First Patient in Phase 3 Program of MELT-300 Opioid-Free Sedationhttps://modernod.com/news/melt-pharmaceuticals-doses-first-patient-in-pivotal-phase-3-program-of-melt-300-opioid-free-sedation/2482312/Melt Pharmaceuticals announced that the first patient has been dosed in its phase 3 program evaluating the safety and efficacy of its lead product candidate, MELT-300, a non‑IV, non-opioid tablet that combines fixed doses of midazolam (3mg) and ketamine (50mg). MELT-300 is administered sublingual
- Nidek Launches the RS-1 Glauvas Optical Coherence Tomography Devicehttps://modernod.com/news/nidek-launches-the-rs-1-glauvas-optical-coherence-tomography/2482304/Nidek has launched the RS-1 Glauvas Optical Coherence Tomography (OCT). The RS-1 Glauvas has up to 250kHz scan speed, wide and deep area imaging, operability, and deep learning-based analytics. The incorporation of 250,000 A-scans/s accelerates the workflow by reducing capture
- Bausch + Lomb Receives Health Canada Approval for enVista Envy Full Visual Range IOLhttps://modernod.com/news/bausch-lomb-receives-health-canada-approval-for-envista-envy-full-visual-range-iol/2482293/Health Canada has approved Bausch+Lomb's enVista Envy full visual range IOL. This is the first regulatory approval of the new lens, which is designed to offer a full range of vision with dysphotopsia tolerance on the enVista IOL platform. “enVista Envy
- New Research Reveals COVID-19 Virus Could Damage Visionhttps://modernod.com/news/new-research-reveals-covid-19-virus-could-damage-vision/2482285/Researchers at the University of Missouri School of Medicine have discovered the virus that causes COVID-19 can breach the blood-retinal barrier with potential long-term consequences in the eye. Using a humanized ACE2 mice model, research led by Pawan Kumar Singh, PhD, an assi
- Humonix Biosciences Appoints Karen Torrejon, PhD, as New CEOhttps://modernod.com/news/humonix-biosciences-appoints-karen-torrejon-phd-as-new-ceo/2482275/Humonix Biosciences announced the appointment of Karen Torrejon, PhD, as the new Chief Executive Officer. Dr. Torrejon, who originally founded the company in 2014, will now be leading the company as it transitions into a broader, science-driven platform. Humonix’s platform has bee
- Staar Surgical Announces Agreement in US with IQ Laser Visionhttps://modernod.com/news/staar-surgical-announces-agreement-in-us-with-iq-laser-vision/2482269/Staar Surgical announced a strategic agreement with IQ Laser Vision, which has locations across California and Texas. IQ Laser Vision will make EVO ICL lenses a primary option for patients seeking surgical vision correction within the range of -3D to -20D. IQ Laser V
- Retina Community Mourns the Loss of Ramin Tadayoni, MD, PhDhttps://modernod.com/news/retina-community-mourns-the-loss-of-ramin-tadayoni-md-phd/2482240/Prof. Ramin Tadayoni, MD, PhD, a giant in the global retina community, passed away on Friday. A respected leader, investigator, mentor, and educator, Prof. Tadayoni was the head of the ophthalmology department at the Fondation Adolphe de Rothschild and the Lariboisière and Saint-
- BVI’s Podeye Hydrophobic Monofocal IOL Launched in Japanhttps://modernod.com/news/bvis-podeye-hydrophobic-monofocal-iol-launched-in-japan/2482239/BVI Medical announced the launch of the Podeye hydrophobic monofocal intraocular lenses (IOL) in Japan after receiving approval by the Japanese Pharmaceuticals and Medical Devices Agency. Podeye is now available for commercial use and available to surgeons across the country. The Podeye
- Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating Aqueous Outflow Restorative Procedure with OMNIhttps://modernod.com/news/sight-sciences-announces-the-publication-of-large-scale-real-world-migs-study-demonstrating-aqueous-outflow-restorative-procedure-with-omni/2482226/Sight Sciences announced the results as published in the American Journal of Ophthalmology (AJO) International of a large scale, comparative real-world clinical outcomes study of patients treated by three leading, minimally invasive glaucoma surgery (MIGS) technologies.
- Oculis Appoints Snehal Shah, PharmD, as President of Research & Developmenthttps://modernod.com/news/oculis-appoints-snehal-shah-pharmd-as-president-of-research-development/2482225/Oculis announced the appointment of Snehal Shah, PharmD, executive leader with over two decades of research & development (R&D) and regulatory experience, to the role of President of R&D. In this new role, Dr. Shah will be responsible for leading research and developmen